Hepatitis B vaccine recombinant - Beijing Minhai Biotechnology

Drug Profile

Hepatitis B vaccine recombinant - Beijing Minhai Biotechnology

Alternative Names: Recombinant Hepatitis B vaccine - Beijing Minhai Biotechnology

Latest Information Update: 02 Sep 2015

Price : $50

At a glance

  • Originator Beijing Minhai Biotechnology
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 02 Sep 2015 Phase-I clinical trials in Hepatitis B (Prevention) in China (Parenteral) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top